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Abstract
Background: Non-small cell lung cancer (NSCLC) is the foremost cause of cancer-related death in Western countries, which
is due partly to the propensity of NSCLC cells to metastasize. The biologic basis for NSCLC metastasis is not well understood.
Methodology/Principal Findings: Here we addressed this deficiency by transcriptionally profiling tumors from a genetic
mouse model of human lung adenocarcinoma that develops metastatic disease owing to the expression of K-ras
G12D and
p53
R172H. We identified 2,209 genes that were differentially expressed in distant metastases relative to matched lung tumors.
Mining of publicly available data bases revealed this expression signature in a subset of NSCLC patients who had a poorer
prognosis than those without the signature.
Conclusions/Significance: These findings provide evidence that K-ras
G12D; p53
R172H mice recapitulate features of human
NSCLC metastasis and will provide a useful platform on which to study the biologic basis for lung adenocarcinoma
metastasis and its prevention by novel agents.
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Introduction
Non-small cell lung cancer (NSCLC) is the leading cause of
cancer-related death in the United States and other western
countries. Approximately two thirds of patients are diagnosed at
an advanced stage, and of the remaining patients who undergo
curative surgery, 30–50% have a recurrence with metastatic
disease. Thus, a better understanding of the biologic underpin-
nings of metastatic disease is of paramount importance. Metastasis
research in lung cancer has been hampered by the lack of good
animal models and the difficulty in studying disease progression
and metastasis in patients. This has resulted in a reliance on in vitro
cell cultures derived from patients or immunodeficient animal
xenograft studies. As a result, we understand much more about
cancer cell-autonomous genetic and epigenetic changes than about
the role of the supportive microenvironment. To address this need,
we and other investigators have developed mouse models in which
lung adenocarcinomas arise spontaneously owing to mutant K-ras
alleles expressed inducibly, conditionally, or somatically
[1,2,3,4,5]. Although an improvement, these models uniformly
lack metastatic potential, a serious deficiency given that metastasis
is the most common cause of death in NSCLC patients.
A p53 missense mutation, R175H, found in Li-Fraumeni
syndrome patients and in a subset of NSCLC patients, is a
structural mutation that exhibits loss of function owing to
inactivation of p53 transcriptional activity [6,7,8]. Mutation of
the corresponding arginine (R172H) in murine p53 has been
previously introduced into the mouse as a knock-in allele. To
evaluate the importance of p53
R172H as a contributing event in
lung tumorigenesis, p53
R172HDG mice were previously mated with
Kras
LA1 mice, which develop lung adenocarcinomas owing to
somatic activation of a latent Kras
G12D allele, but rarely
metastasize [4]. Mice were generated that were heterozygous for
Kras
LA1 alone, p53
R172HDG alone, or both alleles [9]. In the
absence of mutant K-ras, lung adenocarcinomas were rare (13% of
p53
R172HDG/+ mice). Although the presence or absence of the
mutant p53 allele did not affect the frequency of lung
adenocarcinomas in Kras
LA1 mice (62.5% versus 70.8%, respec-
tively), metastases were much more frequent in those with p53
mutations than in those without (36.5% versus 4.5%). In the
Kras
LA1/+; p53
R172HDG/+ mice, metastases were found at sites
frequently observed in NSCLC patients, including the mediastinal
lymph nodes, heart, parietal pleura, diaphragm, liver, adrenal
gland, kidney, mesentery, pancreas, and subcutaneous tissues. The
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5401Figure 1. A gene expression signature of spontaneous metastasis in a K-ras/p53 mutant mouse model. (A) Gene expression profiles of
tumor metastases were compared to the corresponding primary tumor to define the metastasis gene signature (P,0.01, paired t-test). Each row of
the expression matrix represents a gene and each column represents a profiled sample; relative gene expression (metastasis: primary) is represented
using a yellow–blue color scale. Genes defined as cell cycle-related by either the Whitfield signature [16] or by Gene Ontology (GO) are indicated. (B)
The expression patterns of the mouse model metastasis signature in a panel of human lung tumors from Bhattacharjee et al. [14]. Tumors showing
‘‘activation’’ of the metastasis signature (as measured by the ‘‘met signature t-score’’) tend to have high expression of the genes high in the mouse
metastases and low expression of the genes low in the mouse metastases. (C) Kaplan-Meier analysis of the human lung tumors comparing the
differences in risk between tumors showing activation (yellow line, t-score.0) and tumors showing deactivation (blue line, t-score,0) of the mouse
model metastasis signature. Log rank test evaluates whether there are significant differences between the two arms. Univariate Cox test evaluates the
association of the met signature t-score with patient outcome, treating the coefficient as a continuous variable. (D) Same as for part C, except that
cell cycle-associated genes (as defined by either Whitfield et al or GO) were first removed from the mouse model metastasis signature prior to
deriving the met signature t-score.
doi:10.1371/journal.pone.0005401.g001
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of the murine tumors, which mimics the wild-type p53 allelic
deletion observed in tumors from Li-Fraumeni patients. Collec-
tively, these findings suggest that Kras
LA1/+; p53
R172HDG/+ mice
are a useful model for the study of metastasis in NSCLC patients.
In this study, we sought to better understand the biologic basis
for metastasis in Kras
LA1/+; p53
R172HDG/+ mice. Tumors from the
lung and distant metastatic sites were transcriptionally profiled,
from which we derived a metastasis signature defined as those
genes that were differentially expressed in the metastases relative
to paired primary lung tumors. Data mining of publicly-available
expression profiles revealed this signature in a subset of primary
tumors from NSCLC patients who had poor prognosis. We
conclude that Kras
LA1/+; p53
R172HDG/+ mice are a useful tool for
the study of lung adenocarcinoma metastasis.
Materials and Methods
Mouse studies
We followed the guidelines set forth by the Institutional Animal
Care and Use Committee of The University of Texas, M. D.





Primary lung adenocarcinomas and metastases from
p53
R172HDg/+ K-ras
LA1/+ mice were isolated, carefully dissected to
remove the adjacent tissue, snap-frozen in liquid nitrogen and
stored at 280u until use [9]. Part of each dissected tumor was
histologically evaluated by a board-certified pathologist.
Gene expression profiling
Total RNA from the p53
R172HDg/+ K-ras
LA1/+ tumors was
extracted by Trizol (Invitrogen) and purified with an RNeasy kit
(Qiagen). RNA quality and quantity were evaluated on an Agilent
Bioanalyzer following the manufacture’s recommendations (Agi-
lent Technologies). Synthesis of cRNA and hybridization to Mouse
Expression Array 430A 2.0 chips were performed following
Affymetrix protocols (Affymetrix, Inc.).
Microarray data analysis
After scanning and low-level quantification using Microarray
Suite (Affymetrix), DNA Chip (dChip) analyzer [10] was used to
estimate expression values, using the PM/MM difference model
and invariant set normalization. Present call rates for the tumor
profiles ranged from 51% to 63%, and none of the profiles were
flagged by dChip as potential outliers. Two-sided t-tests using log-
transformed data determined significant differences in mean gene
mRNA levels between groups of paired samples. Fold changes
between groups were estimated by taking the averages of the
metastasis/primary log ratios. Expression values were visualized as
color maps using the Java TreeView software [11]. Gene
Ontology (GO) annotation terms were searched within gene sets
using SigTerms [12]. Genes arising from the syngenic tumor
dataset were clustered using the technique described in [13].
Expression profiles were deposited into the Gene Expression
Omnibus data repository (GSE accession #14449) and are
MIAME compliant.
In order to score each human lung tumor within a set for
similarity to our gene signature of spontaneous metastases
(Figure 1), we derived a ‘‘t-score’’ for each human tumor in
relation to the mouse metastasis signature, similar to what we have
done in previous analyses [13]. The t-score was defined as the
Pearson’s correlation between the mouse metastasis gene signature
pattern (using ‘‘1’’ and ‘‘21’’, for up and down, respectively) and
the human tumor’s expression values (which is essentially a t-
statistic comparing the average of the up genes with that of the
down genes within each human tumor). The gene expression
values in the human tumor datasets were first normalized to
standard deviations from the mean before computing the t-score.
The mapping of transcripts or genes between the mouse signature
and the human tumor array datasets was made on the Entrez
Gene identifier; where multiple human array probe sets referenced
the same gene, the probe set with the highest variation represented
the gene.
Results
Transcriptional profiling of spontaneous tumors from
Kras
LA1/+; p53
R172HDG/+ mice reveals a metastasis
signature that is prognostic in NSCLC patients
We postulated that the biologic processes mediating metastasis
in Kras
LA1/+; p53
R172HDG/+ mice would recapitulate those in a
subset of NSCLC patients. To test this, the transcriptome of
tumors from Kras
LA1/+; p53
R172HDG/+ mice were profiled, and the
derived metastasis signature, which was defined as those genes that
were differentially expressed in the metastases relative to paired
primary lung tumors, was compared to previously published
expression profiles from lung adenocarcinomas from several
patient cohorts [14,15]. Primary lung and matched metastastic
tumor tissues from 4 mice were removed (Table 1); RNA was
purified and subjected to Affymetrix gene expression profiling.
Using each primary lung tumor (n=4, 1 per mouse) as the
reference for the corresponding metastases (n=9, 1 to 3 per
mouse), 2,209 genes were found to be differentially expressed (p
value,0.01, paired t-test), 802 of which were increased and 1,407
were decreased (Figure 1A). Listed in Table 2 and Figure S1 are
the most over- and under-expressed genes in the metastases and
the entire set of 2,209 differentially expressed genes, respectively.
We validated differential expression of genes involved in processes
relevant to metastasis, including BUB-1, a regulator of genomic
integrity and mitosis, VIM, a marker of epithelial-to-mesenchymal
Table 1. Tumors Used for Gene Expression Analysis.
Genotype Mouse # Tumor type and location
p53R172HDg/+ K-rasLA1/+ mouse 1 AC18-adenocarcinoma, lung
AC19-metastasis, liver
AC20-metastasis, body wall 1
AC21-metastasis, body wall 2
p53R172HDg/+ K-rasLA1/+ mouse 2 AC22-adenocarcinoma, lung
AC23-metastasis, liver
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quantitative reverse transcriptase PCR analysis (Figure 2).
Enrichment analysis (Fisher’s exact test using Gene Ontology
terms) of those genes with increased expression revealed highly
significant enrichment in genes with the terms ‘cell cycle’ (45
genes, enrichment p=1.4E-9), ‘kinetochore’ (8 genes, p=1.5E-6),
‘pericentric chromosome-binding’ (10 genes, p=3.4E-6), ‘DNA
replication’ (17 genes, p=6.0E-6), and ‘DNA-binding’ (103 genes,
p=0.0001), whereas analysis of the genes that were decreased
revealed enrichment in genes with the terms ‘membrane-binding’
(391 genes, p=9.8E-12), ‘integral-to-membrane’ (333 genes,
p=5.1E-9), ‘lysosomal’ (24 genes, p=1.2E-5), and ‘golgi appara-
Table 2. Top named genes differentially expressed (P,0.01) between primary tumors and metastasis.
Affymetrix
probe set Gene Title Gene Symbol
fold change, met vs
primary (log2)
Higher in metastasis (ranked by fold change)
1426278_at interferon, alpha-inducible protein 27 Ifi27 2.034805214
1418588_at neurensin 1 Nrsn1 2.015696907
1423439_at phosphoenolpyruvate carboxykinase 1, cytosolic Pck1 2.008413051
1436504_x_at apolipoprotein A-IV Apoa4 1.899587267
1448226_at ribonucleotide reductase M2 Rrm2 1.856439628
1427465_at ATPase, Na+/K+ transporting, alpha 2 polypeptide Atp1a2 1.80166054
1419943_s_at cyclin B1 Ccnb1 1.718304491
1460347_at keratin 14 Krt14 1.650172294
1438009_at similar to histone 2a MGC73635 1.628484792
1455439_a_at lectin, galactose binding, soluble 1 Lgals1 1.619253423
1431164_at Ras-related GTP binding D Rragd 1.616979652
1451367_at COP9 (constitutive photomorphogenic) homolog, subunit 6 (Arabidopsis thaliana) Cops6 1.616770969
1426920_x_at integrin beta 1 (fibronectin receptor beta) Itgb1 1.607222931
1416301_a_at early B-cell factor 1 Ebf1 1.604511281
1422006_at eukaryotic translation initiation factor 2-alpha kinase 2 Eif2ak2 1.584624642
1448314_at cell division cycle 2 homolog A (S. pombe) Cdc2a 1.564221952
1420575_at metallothionein 3 Mt3 1.543842484
1419513_a_at ect2 oncogene Ect2 1.525512151
1456566_x_at RNA binding motif protein 14 Rbm14 1.496890793
1423607_at lumican Lum 1.4854932
Lower in metastasis (ranked by fold change)
1452543_a_at secretoglobin, family 1A, member 1 (uteroglobin) Scgb1a1 25.605051087
1435386_at Von Willebrand factor homolog Vwf 24.501907686
1423436_at glutathione S-transferase, alpha 3 Gsta3 23.815193669
1421802_at eosinophil-associated, ribonuclease A family, member 1 Ear1 23.81250599
1454681_at RNA binding motif protein 35A Rbm35a 23.599463463
1416236_a_at epithelial V-like antigen 1 Eva1 23.579430627
1422905_s_at flavin containing monooxygenase 2 Fmo2 23.576820392
1419475_a_at ets homologous factor Ehf 23.487510424
1450494_x_at CEA-related cell adhesion molecule 1 Ceacam1 23.394496
1423914_at RIKEN cDNA C630004H02 gene C630004H02Rik 23.049771708
1423323_at tumor-associated calcium signal transducer 2 Tacstd2 23.037340132
1429626_at surfactant associated protein A1 Sftpa1 22.893831126
1449081_at carboxylesterase 3 Ces3 22.88430922
1426332_a_at claudin 3 Cldn3 22.869993162
1422334_a_at surfactant associated protein A1 Sftpa1 22.7988671
1417797_a_at RIKEN cDNA 1810019J16 gene 1810019J16Rik 22.785446923
1449184_at peptidoglycan recognition protein 1 Pglyrp1 22.713447175
1418639_at surfactant associated protein C Sftpc 22.710279321
1417275_at myelin and lymphocyte protein, T-cell differentiation protein Mal 22.707840748
1421404_at chemokine (C-X-C motif) ligand 15 Cxcl15 22.682133804
doi:10.1371/journal.pone.0005401.t002
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S2). A significant number of genes appeared to be related to cell
cycle functions (Fig. 1A), as defined by the Gene Ontology
classification or using the signature from Whitfield et al. [16].
We next compared these results with a publicly-available
database containing expression profiles of resected, early-stage
NSCLC specimens from the dataset by Bhattacharjee et al. [14],
for which clinical outcome data was available. Focusing the
analysis on those patients with lung adenocarcinomas (n=73), we
examined whether the murine metastasis signature is present in
patients and whether its presence correlates with poor clinical
outcome, which would be expected if the signature indicates the
presence of tumor cells with the capacity to metastasize. Of the
1,407 genes with differential expression in the murine metastasis
signature, 982 (70%) genes were represented in the human tumor
expression profiles. Each human lung tumor was assigned a
metastasis t-score, which gave a measure of how the human tumor
recapitulated the patterns of over- and under-expression observed
in the murine metastasis signature (Fig. 1B). Using this approach,
we found that the level of enrichment of the Bhattacharjee tumors
for the murine metastasis signature was informative from a
prognostic standpoint, whether or not the genes related to cell
cycle were included (Fig. 1C and 1D). Those patients with the
signature (t-score.0) had a shorter median disease-free survival
duration than did those without the signature (p,0.001, Kaplan-
Meier analysis) (Fig. 1C).
Using the same parameters and methodology, we examined the
four human NSCLC datasets presented in the Director’s
Challenge study [15] and found that, for two of the cohorts
(MSKCC and HLM) in the Director’s Challenge study, those
patients with tumors that had the metastasis signature (t-score.0)
had a shorter progression-free survival than did those without the
signature (p,=0.03 for each, Kaplan-Meier analysis, Fig. 3A &
B). This prognostic trend was apparent in the Dana-Farber
Cancer Institute (CAN/DF) cohort, though not with statistical
significance (p=0.13, Fig. 3C). The Michigan cohort, however,
did not show any prognostic trend for the mouse metastasis
signature (Fig. 3D), though among the 395 genes that were
increased in the murine metastasis signature and represented on
the Michigan arrays, 141 genes correlated (p,0.01, t-test) with
poorly-differentiated versus well-differentiated histology (enrich-
ment p value,1.0610
215). An overall analysis of the four datasets
combined did demonstrate significant prognostic ability in the
human tumors by the murine metastasis signature (p=0.01,
Figure 2. Verification of mRNA expression levels by Q-PCR. Total RNA from spontaneous tumors for gene expression profiling was reverse-
transcribed with the First-Strand cDNA Synthesis Kit (Amersham Bioscience). Real-time PCR reactions were prepared in duplicate in a 96- or 384-well
clear optical reaction plate (Applied Biosystems), using SybrGreen master mix (Applied Biosystems), and run on an ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems). Normal lung tissue from wild-type mice was used for calibration. Glyceraldhyde-3-phosphate dehydrogenase
(GAPDH) was used as the endogenous control. The relative level of a gene was determined by calculating DDCt, based on the formula
DDCt=(sample Ct [gene]2sample Ct [GAPDH])2(normal lung Ct [gene]2normal lung Ct [GAPDH]).
doi:10.1371/journal.pone.0005401.g002
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murine signature without the cell cycle genes was applied to the
datasets (Figure S3). On the basis of these findings, we conclude
that the murine model recapitulated biologic features of the subset




mice to genes that have been implicated in metastasis of human
tumors, we examined whether the murine signature overlapped with
gene expression profiles of human primary versus metastatic tumor
specimens [17,18], which revealed a significant degree of overlap (P
value,0.05, described in detail in Figure S4). Of the 738 genes that
were increased (p,0.05), in the human metastasis relative to that of
primary tumor, 49 were among the increased expression gene set in
the murine signature (enrichment p=0.001).
Figure 3. The spontaneous mouse metastasis signature is associated with poor prognosis in human lung tumor profile datasets
from the Director’s Challenge Consortium. Kaplan-Meier analysis comparing the differences in risk between human lung tumors showing
activation (yellow line, t-score.0) and tumors showing deactivation (blue line, t-score,0) of the mouse model metastasis signature. Datasets from
the study by Shedden et al. [15] and represent four independent cohorts from (A) Memorial Sloan-Kettering Cancer Center (MSK), (B) Moffitt Cancer
Center (HLM), (C) Dana-Farber Cancer Institute (CAN/DF), and (D) University of Michigan Cancer Center (MICH). (E) Kaplan-Meier analysis of tumors
combined from all four datasets (N=362).
doi:10.1371/journal.pone.0005401.g003
Metastasis Expression Profiles
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In this study, we sought to examine the fidelity of the metastatic
process in Kras
LA1/+; p53
R172HDG/+ mice to that of NSCLC patients
by performing transcriptional profiling studies. We identified a
metastasis expression signature in Kras
LA1/+; p53
R172HDG/+ mice
that was present in primary tumors from NSCLC patients who
had poor prognosis. Based upon the ability of the murine
metastasis signature to discriminate patient outcome, we conclude
that the murine tumors recapitulated features of human lung
adenocarcinoma. We do not mean to imply that this signature is
clinically useful in a prognostic or predictive fashion, but simply
interpret it as evidence of the potential usefulness and relevance of
the model for studying the biology of human lung adenocarcinoma
metastasis.
We examined whether the murine metastasis signature
overlapped with genes identified from five NSCLC patient
cohorts reported in two studies [14,15] and found overlap in a
subset of patients. The presence of the murine signature correlated
with poor clinical outcome in only three of the five cohorts. We
can only speculate about why the correlation with clinical
outcome differed among the cohorts but suspect that it relates
to tumor biologic differences. Tumor histology and disease stage
are unlikely to be relevant variables because the distributions of
these variables did not differ significantly between the cohorts
examined, but patient demographic variables yet to be examined
might prove relevant. The two NSCLC cohorts we used for data
mining have reported both overall survival and disease progres-
sion-free survival [14,15]. Although the murine metastasis
signature identified patients with a poor clinical outcome with
both clinical outcomes, trends were more significant with
progression-free survival (Figure S3), implying that the genes in
the murine signature impact biologic processes involved in disease
recurrence but not other processes relevant to the survival of
patients with recurrent disease, such as resistance to cancer
treatments. Of note, the murine metastasis signature did not
correlate with NSCLC K-ras mutational status, which was
reported by Bhattacharjee et al. [14].
The increased-expression gene set in the metastasis signature
was enriched in cell cycle genes, but the prognostic power of the
metastasis signature was not diminished by the removal of cell
cycle genes, suggesting that the metastatic capacity of lung tumor
cells in Kras
LA1/+; p53
R172HDG/+ mice was not related simply to
their proliferative potential and that other genes involved in
biologic processes relevant to metastasis, such as tumor cell
invasive potential, might have contributed. Of note, in that regard,
were genes in the decreased-expression gene set that control cell
polarity (Cldn3, Pard3, Pard6b, Dlgh1, and Crb3) and cell-cell
attachments (Ccam1 and Cask2). Loss of polarity and cell-cell
contacts are features of epithelial cells that have undergone
epithelial-to-mesenchymal transition (EMT), a phenotypic change
associated with enhanced invasive and metastatic properties in
tumor cells [19]. Other genes typically expressed in mesenchymal
cells, including Vim and Cdh2, were more highly expressed in the
metastases than in the primary lung tumors that arose in K-ras
LA/+
p53
R172HDg/+ mice. Whether these changes reflect a phenotypic
change that contributed to the metastatic capacity of these cells is
currently under investigation and will be reported on separately.
We conclude that Kras
LA1/+; p53
R172HDG mice will provide a
useful platform to better understand the basic biologic processes
that underlie metastasis, to identify biologic targets for the
prevention and treatment of metastasis, and to test the efficacy
of novel agents directed against those targets in preclinical studies.
Such studies could have a tremendous impact on global health
given that NSCLC is the most common cause of cancer-related
death in Western countries, and metastasis is the most common
cause of death in NSCLC patients.
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